Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 594 participants.

Also called NCT01887600

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 594 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01887600
  • EudraCT 2012-005180-27
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belarus, Belgium, Bulgaria, Colombia, Dominican Republic, Estonia, Georgia, Greece, Guatemala, Hungary, Italy, Panama, Peru, Poland, Romania, Russia, Serbia, South Africa, Spain, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01887600. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-03 (actual); primary completion 2017-11-01 (actual). Results posted on 2020-12-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Acronym
ALPS
Condition
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Intervention (Drug)
Roxadustat
Intervention (Drug)
Placebo
Lead sponsor
Astellas Pharma Europe B.V. (class: industry)
Collaborator
Kyntra Bio (class: industry)

Record details

Record id
cardio:ct-nct01887600
Content hash
94d7528cd45a4128ba84518152befc5a7db7e9979bcdc9fd35b9e111f3f05397